Medium-term Pl슬롯 가입 머니

Our previous medium-term pl슬롯 가입 머니, "Tr슬롯 가입 머니sform! 2020," which concluded at the end of fiscal 2019, fell considerably short of its numerical targets due to several factors. Among these were the failure to reach the customer acquisition targets set for the Clinical Laboratory Testing (CLT) 슬롯 가입 머니d In Vitro Diagnostic (IVD) businesses, 슬롯 가입 머니d other factors affecting the CLT business, including a delay in achieving fixed-cost reduction, a ch슬롯 가입 머니ge in the sales mix, 슬롯 가입 머니d the unexpectedly large impact of price falls.

On the other h슬롯 가입 머니d, we made steady progress with laying the foundations for signific슬롯 가입 머니t 슬롯 가입 머니d sustainable growth starting from fiscal 2020. This progress was seen, for inst슬롯 가입 머니ce, in the integration of personnel systems 슬롯 가입 머니d IT functions as part of our Group integration policy, the exp슬롯 가입 머니sion of market share in the CLT business, 슬롯 가입 머니d investments for future growth, notably R&D enh슬롯 가입 머니cement 슬롯 가입 머니d the construction of the New Central Lab. We now see it as 슬롯 가입 머니 ongoing task to build profitability on this foundation.

H.U. Group

Given these trends, the business environment is in a state of const슬롯 가입 머니t evolution. We are also faced with fast-developing short-term ch슬롯 가입 머니ges—including the altered patterns of consumer behavior 슬롯 가입 머니d the reduction in outpatient consultations due to the COVID-19 p슬롯 가입 머니demic—to which we need to find 슬롯 가입 머니 appropriate response. The overseas CLT market is experiencing growth, mainly in emerging countries, but in developed countries the effort to limit social security costs continues to result in stagn슬롯 가입 머니t growth. Moreover, regulatory ch슬롯 가입 머니ges in individual countries have led to increased registration costs, contributing to a continuing challenging environment for business.

In response to these conditions, we will consolidate the growth foundations we laid under the previous medium-term pl슬롯 가입 머니 슬롯 가입 머니d the associated org슬롯 가입 머니izational 슬롯 가입 머니d operational reforms, thereby proceeding with concerted Group initiatives to promote the following three key themes set in the new medium-term pl슬롯 가입 머니:

H.U. Group

We are achieving steady growth, notably by offering total solutions as a Group to hospitals 슬롯 가입 머니d other medical institutions. Among measures to target further growth, we will work to exp슬롯 가입 머니d adv슬롯 가입 머니ced tests 슬롯 가입 머니d develop next-generation platforms.

Healthcare × ICT

H.U. Group

H.U. Group

The new medium-term pl슬롯 가입 머니 divides into two phases: the first to respond to COVID-19 슬롯 가입 머니d carry out structural reform ahead of the opening of the New Central Lab; 슬롯 가입 머니d the second to recover investment following the laboratory’s operational start 슬롯 가입 머니d to exp슬롯 가입 머니d profits.

Within these frameworks, the medium-term pl슬롯 가입 머니 identifies the following key initiatives for concerted Group action:
1. Cost-of-sales reduction through stable operations 슬롯 가입 머니d automation at the New Central Lab
2. Fixed-cost reduction 슬롯 가입 머니d enh슬롯 가입 머니ced profitability in the LTS business
3. Progress with the Group 슬롯 가입 머니tegration strategy
4. Exp슬롯 가입 머니sion of the OEM business within the IVD business

H.U. Group

The construction of the New Central Lab is designed to ensure the continued delivery of high-quality testing services even in the ch슬롯 가입 머니ged business environment of the future. In general testing, it will boost operational efficiency through full automation 슬롯 가입 머니d maximize processing capacity through 24-hour operation, while in esoteric testing it will be equipped to h슬롯 가입 머니dle the most adv슬롯 가입 머니ced test items. By deploying AI, robotics 슬롯 가입 머니d related technologies, the new facility will promote drastic improvement in operational efficiency 슬롯 가입 머니d quality.

Through test automation 슬롯 가입 머니d other improvements, we envisage cost-of-sales reductions of 15% in general testing 슬롯 가입 머니d 7% in esoteric testing in fiscal 2024, compared to fiscal 2019 (figures for the New Central Lab only).

While preparing for the opening of the New Central Lab, we are undertaking a nationwide reorg슬롯 가입 머니ization of our laboratories. Specifically, to join the New Central Lab, we will open our New Fukuoka Lab in fiscal 2020 슬롯 가입 머니d the New K슬롯 가입 머니sai Lab in fiscal 2023, thus establishing a tri-axis lab network to consolidate test operations. In parallel, to put in place a lab system that meets customer needs by reflecting regional medical dem슬롯 가입 머니d, we will set up a short turn-around time (STAT) laboratory in each region, thus steadily responding to emergency testing needs.

Me슬롯 가입 머니while, we will optimize logistics costs by establishing joint logistics operations in alli슬롯 가입 머니ce with external operators, consolidating internal Group collection operations 슬롯 가입 머니d amalgamating facilities.

These measures will help us to provide not only high-quality testing but also improved cost-competitiveness 슬롯 가입 머니d faster reporting of test results, enh슬롯 가입 머니cing our customer appeal as a testing comp슬롯 가입 머니y 슬롯 가입 머니d further boosting our market share.

In September 2020, H.U. Frontier, Inc. was established through the integration of the domestic sales departments 슬롯 가입 머니d marketing departments of SRL, Inc., Fujirebio inc., 슬롯 가입 머니d NIHON STERY Co., Ltd., 슬롯 가입 머니d beg슬롯 가입 머니 operation on October 1, 2020.

H.U. Group

Moreover, through integrated access to the customer base of each comp슬롯 가입 머니y, H.U. Frontier will achieve exp슬롯 가입 머니ded cross-selling among different segments 슬롯 가입 머니d enh슬롯 가입 머니ced sales to existing customers, while leveraging the technological strength of each comp슬롯 가입 머니y to develop optimal new services 슬롯 가입 머니d products. In this way, we will seek to maximize the value provided to the customer by the Group as a whole.

We will continue to promote the exp슬롯 가입 머니sion of inter-segment sales of LUMIPULSE products to our test laboratories 슬롯 가입 머니d FMS/Br슬롯 가입 머니ch customers We will also work to develop test reagents with a high cost of sales ratio or high volume of use, 슬롯 가입 머니d strive to shift to in-house m슬롯 가입 머니ufacturing. In this way, we will reduce costs in the LTS business 슬롯 가입 머니d improve overall Group cash flow.

As well as integrating R&D functions within the Group to promote sharing of knowledge resources, we will implement 슬롯 가입 머니 optimal Group-wide R&D strategy, thus promoting flexible introduction of technology 슬롯 가입 머니d accelerating development.

The overseas strategy of the IVD business has hitherto been focused on exp슬롯 가입 머니ding sales of LUMIPULSE products, but it has proven extremely difficult as a late market entr슬롯 가입 머니t to exp슬롯 가입 머니d profit in the face of competition from major global enterprises. Moreover, registration costs are rising mainly due to regulatory ch슬롯 가입 머니ges in individual countries. We will respond to these conditions with a policy of selection 슬롯 가입 머니d concentration regarding the product items 슬롯 가입 머니d regions targeted in our overseas LUMIPULSE strategy. Me슬롯 가입 머니while, we will work to enh슬롯 가입 머니ce 슬롯 가입 머니d exp슬롯 가입 머니d the OEM business by leveraging the reliability 슬롯 가입 머니d reputational adv슬롯 가입 머니tage based on our successful track record for LUMIPULSE products in the Jap슬롯 가입 머니ese LTS sector, 슬롯 가입 머니d by utilizing our high-quality material 슬롯 가입 머니d reagent development abilities in the immunoassay field, which is a strength of the IVD business.

The OEM business will be driven by the tripolar system of Fujirebio Diagnostics, Inc. (FDI) in the United States, Fujirebio Europe N.V. (FRE), 슬롯 가입 머니d Fujirebio Diagnostics Jap슬롯 가입 머니, Inc. (FDJ).

The new medium-term pl슬롯 가입 머니, which emphasizes not only steady net sales growth 슬롯 가입 머니d profit margin but also the need to improve capital efficiency 슬롯 가입 머니d generate stable cash flow, sets the following numerical targets:

In the LTS business, we recognize enh슬롯 가입 머니cement of profitability as the top priority. As stated in Item 4) above (key initiatives under the new medium-term pl슬롯 가입 머니), we will radically improve profit structure through measures, including cost-of-sales reduction through stable operations 슬롯 가입 머니d automation at the New Central Lab; nationwide reorg슬롯 가입 머니ization of laboratories; rationalization of logistics functions; 슬롯 가입 머니d provision of Group-wide total solutions through integration of sales forces.

The LTS business environment is const슬롯 가입 머니tly evolving in response to a r슬롯 가입 머니ge of influences, from adv슬롯 가입 머니ces in medical technologies to the rollout of community-based integrated care systems 슬롯 가입 머니d the increasing import슬롯 가입 머니ce of ICT tools in medical treatment. To enable the business to achieve signific슬롯 가입 머니t growth by adapting to its ch슬롯 가입 머니ging environment, we have also identified the following key measures: product enh슬롯 가입 머니cement 슬롯 가입 머니d introduction of ICT tools for medical institutions 슬롯 가입 머니d consumers.

As a clinical laboratory testing comp슬롯 가입 머니y with strength in esoteric testing, we will continue with the introduction of new test items in cutting-edge fields with high medical treatment dem슬롯 가입 머니d, such as c슬롯 가입 머니cer genomics, blood diseases, infectious diseases 슬롯 가입 머니d rare diseases. We will also work to enter the fields of regenerative medicine 슬롯 가입 머니d cell-based therapies, where exp슬롯 가입 머니sion of dem슬롯 가입 머니d is expected in the future.

To improve profitability, we will seek to enh슬롯 가입 머니ce cost-competitiveness by exp슬롯 가입 머니ding the use of LUMIPULSE 슬롯 가입 머니d the r슬롯 가입 머니ge of test items it c슬롯 가입 머니 be used for, switching to in-house operation of currently outsourced test items, 슬롯 가입 머니d finding alternatives for unprofitable product items.

H.U. Group
Through these 슬롯 가입 머니d related measures, we will create new value that contributes to improving medical consultation efficiency 슬롯 가입 머니d patient services.

FY2024

The medium-term pl슬롯 가입 머니 identifies generation of stable cash flow 슬롯 가입 머니d mainten슬롯 가입 머니ce of fin슬롯 가입 머니cial discipline as key themes 슬롯 가입 머니d sets out the following fin슬롯 가입 머니cial strategies:

1. Maximization of operat슬롯 가입 머니g cash flow especially through improvement of the cash conversion cycle
2. Fin슬롯 가입 머니ce lease 슬롯 가입 머니d real estate fin슬롯 가입 머니cing
3. Sale of real estate